VDAC1 and obesity due to melanocortin 4 receptor deficiency: Pharmacological targeting of VDAC has a significant therapeutic potential in several diseases including cancer, neurodegeneration, cardiovascular, and obesity where altering mitochondrial physiology through VDAC may be beneficial.